These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11788979)

  • 81. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane.
    Briggs A; Fenn P
    Health Econ; 1998 Dec; 7(8):723-40. PubMed ID: 9890333
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Setting priorities in Canadian regional health authorities: a survey of key decision makers.
    Mitton C; Donaldson C
    Health Policy; 2002 Apr; 60(1):39-58. PubMed ID: 11879944
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cost and cost threshold analyses for 12 innovative US HIV linkage and retention in care programs.
    Jain KM; Maulsby C; Brantley M; ; Kim JJ; Zulliger R; Riordan M; Charles V; Holtgrave DR
    AIDS Care; 2016 Sep; 28(9):1199-204. PubMed ID: 27017972
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
    Woods B; Revill P; Sculpher M; Claxton K
    Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision.
    Raftery J
    J Eval Clin Pract; 1999 Nov; 5(4):361-6. PubMed ID: 10579700
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Economics, public health and health care purchasing: the Tayside experience of programme budgeting and marginal analysis.
    Ruta DA; Donaldson C; Gilray I
    J Health Serv Res Policy; 1996 Oct; 1(4):185-93. PubMed ID: 10180869
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
    Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
    Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
    Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
    Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Power and sample size in cost-effectiveness analysis.
    Laska EM; Meisner M; Siegel C
    Med Decis Making; 1999; 19(3):339-43. PubMed ID: 10424840
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Medical rationing as a health strategy.
    Wayland G; Kleiner BH
    Health Manpow Manage; 1997; 23(6):223-8. PubMed ID: 10179094
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Cost-effectiveness--limits between optimization and rationing].
    Ruof J; Schöffski O
    Z Rheumatol; 1998 Oct; 57(5):340-4. PubMed ID: 9864843
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems.
    Birch S; Gafni A
    J Health Econ; 1993 Dec; 12(4):469-76. PubMed ID: 10131757
    [No Abstract]   [Full Text] [Related]  

  • 94. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.
    Zethraeus N; Johannesson M; Jönsson B; Löthgren M; Tambour M
    Pharmacoeconomics; 2003; 21(1):39-48. PubMed ID: 12484802
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
    Eichler HG; Kong SX; Gerth WC; Mavros P; Jönsson B
    Value Health; 2004; 7(5):518-28. PubMed ID: 15367247
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Difficult decisions: weighing treatment costs and benefits.
    Wainio JA
    Hosp Technol Ser; 1995 Jan; 14(1):1-3. PubMed ID: 10140805
    [No Abstract]   [Full Text] [Related]  

  • 98. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
    Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
    Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
    Sendi P
    Pharmacoeconomics; 2021 Feb; 39(2):161-169. PubMed ID: 33128734
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mutually Exclusive Interventions in the Cost-Effectiveness Bookshelf.
    Siverskog J; Henriksson M
    Med Decis Making; 2020 Apr; 40(3):399-403. PubMed ID: 32172657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.